<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602533</url>
  </required_header>
  <id_info>
    <org_study_id>Dolphin</org_study_id>
    <secondary_id>2020-001050-22</secondary_id>
    <nct_id>NCT04602533</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)</brief_title>
  <official_title>A Phase II Randomized Study to Evaluate the Efficacy and Safety of Cisplatin / Etoposide and Concomitant Radiotherapy Combined With Durvalumab Followed by Maintenance Therapy With Durvalumab Versus Cisplatin / Etoposide and Concomitant Radiotherapy in Patients With Limited Disease Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Michael Hopp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johannes Gutenberg University Mainz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Combination of concomitant Radio-Chemotherapy showed a significant improvement (Takada) of OS&#xD;
      and PFS in limited disease SCLC patients. This clinical trial is a prospective, multicenter,&#xD;
      randomized, open-label, parallel group phase II investigator initiated trial (ITT) to&#xD;
      evaluate the efficacy and safety of Durvalumab in combination with&#xD;
      Cisplatin/Etoposide/Radiotherapy in patients with limited disease small-cell lung cancer&#xD;
      (SCLC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial is subdivided in a safety run-in phase and a randomized part with the induction&#xD;
      phase (Radiochemotherapy ± Durvalumab and including prophylactic cranial irradiation (PCI; if&#xD;
      clinically indicated and according to local standard)) followed by the maintenance phase. The&#xD;
      trial starts with the safety run-in phase of 6 patients in Durvalumab group. After the&#xD;
      completion of the first cycle of all 6 patients a safety interim analysis will be performed.&#xD;
      Study should be discontinued if ≥ 2 out of 6 patients within safety run-in phase (first&#xD;
      cycle):&#xD;
&#xD;
        -  show more than 2 AEs CTCAE grade ≥3 related to study drug Durvalumab&#xD;
&#xD;
        -  or develop pneumonitis (CTCAE grade ≥2)&#xD;
&#xD;
        -  or drop out, Otherwise, the trial can continue with randomization. Eligible patients&#xD;
           will be randomized to Durvalumab group or standard of care group 2:1.&#xD;
&#xD;
      Induction phase:&#xD;
&#xD;
      Durvalumab group: Cisplatin (75 mg/m² (BSA) D1) and Etoposide (100 mg/m² (BSA) D1-3) once&#xD;
      every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 2 Gy/d) and additional&#xD;
      Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles according to randomization followed by&#xD;
      prophylactic cranial irradiation (PCI, if clinically indicated and according to local&#xD;
      standard)) Control group: Cisplatin (75 mg/m² (BSA) D1) and Etoposide (100 mg/m² (BSA) D1-3)&#xD;
      once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 2 Gy/d) followed by&#xD;
      prophylactic cranial irradiation (PCI, if clinically indicated and according to local&#xD;
      standard)&#xD;
&#xD;
      Maintenance phase:&#xD;
&#xD;
      In Durvalumab group patients will be treated with Durvalumab once every 4 weeks until disease&#xD;
      progression (radiologic or clinical progression) or unacceptable toxicities, if patients show&#xD;
      at least stable disease after induction phase. Patients with PD after induction phase will&#xD;
      have EoT visit and will be followed up until death.&#xD;
&#xD;
      Patients in control group will have EoT visit and will receive standard of care treatment&#xD;
      until PD and thereafter will be followed up until death.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>18 months</time_frame>
    <description>Progression-free survival (PFS) after 18 months according to iRECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PSF) after other assessments</measure>
    <time_frame>12 months</time_frame>
    <description>Time between first application of trial medication to date of disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>18 months</time_frame>
    <description>Time between first application of trial medication to date of death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>18 months</time_frame>
    <description>Complete Response or Partial Response according to iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>18 months</time_frame>
    <description>Complete Response, Partial Response or Stable Disease according to iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Cancer 30 (QLQ-C30)</measure>
    <time_frame>18 months</time_frame>
    <description>Symptom control assessed by patient-reported quality of life (QoL) with QLQ-C30. The score ranges from 0 to 100. The higher the score the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaire - Lung Cancer 13 (QLQ-LC13)</measure>
    <time_frame>18 months</time_frame>
    <description>Symptom control assessed by patient-reported quality of life (QoL) with QLQ-LC13. The scores ranges from 0 to 100. The higher the score the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol five dimension scale (EQ-5D)</measure>
    <time_frame>18 months</time_frame>
    <description>Symptom control assessed by patient-reported quality of life (QoL) with EQ-5D. The score consists of 5 items on a three step scale and a VAS scale ranging from 0 to 100. The lower the score on the three step scales the better the outcome and the higher the score on the VAS scale the better the outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>18 months</time_frame>
    <description>Treatment emergent adverse events during treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Small Cell Lung Cancer Limited Stage</condition>
  <arm_group>
    <arm_group_label>Durvalumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherapy)&#xD;
Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Induction phase: Radiochemotherapy according to guideline&#xD;
Maintenance: Standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>Induction phase: Durvalumab (1500 mg once every 3 weeks) for 4-6 cycles in combination with standard of care (Radiochemotherap) Maintenance phase: Durvalumab (1500 mg once every 4 weeks) until PD or unacceptable toxicities.</description>
    <arm_group_label>Durvalumab</arm_group_label>
    <other_name>IMFINZI®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>standard of care</intervention_name>
    <description>Radiochemotherapy: Cisplatin (75 mg/m² (BSA) D1) and Etoposide (100 mg/m² (BSA) D1-3) once every 3 weeks for 4-6 cycles and concomitant Radiotherapy (60±6 Gy, 2 Gy/d) followed by prophylactic cranial irradiation (PCI, if clinically indicated and according to local standard))</description>
    <arm_group_label>standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated informed consent of the subject must be available before start of any&#xD;
             specific trial procedures&#xD;
&#xD;
          -  Male or female ≥ 18 years&#xD;
&#xD;
          -  Histological confirmed limited disease small cell lung cancer (stage 2 and 3; T2-4,&#xD;
             N1-3, M0 according UICC8 criteria)&#xD;
&#xD;
          -  Availability of tumor tissue or fresh tumor material for translational research by&#xD;
             central lab testing&#xD;
&#xD;
          -  ECOG PS 0 - 1&#xD;
&#xD;
          -  At least one measurable lesion according RECIST 1.1&#xD;
&#xD;
          -  Body weight &gt; 30 kg&#xD;
&#xD;
          -  Adequate normal organ function&#xD;
&#xD;
               1. Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               2. Absolute neutrophil count (ANC) ≥ 1.5 x109/L&#xD;
&#xD;
               3. Platelet count ≥ 100 x109/L&#xD;
&#xD;
               4. AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal&#xD;
&#xD;
               5. Serum Bilirubin ≤ 1.5 x institutional upper limit of normal&#xD;
&#xD;
               6. Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min calculated by the&#xD;
                  Cockcroft-Gault formula&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks in the discretion of the investigator&#xD;
&#xD;
          -  Ability of subject to understand nature, importance and individual consequences of&#xD;
             clinical trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Extensive disease small cell lung cancer (Tx, Nx, M1; stage IV)&#xD;
&#xD;
          -  Major surgical process within 28 day prior first dose of IMP and/or Radiochemotherapy&#xD;
&#xD;
          -  History of allogenic organ transplantation&#xD;
&#xD;
          -  Active or prior documented autoimmune or inflammatory disorder (including inflammatory&#xD;
             bowel disease [e.g. colitis or Crohn's disease], diverticulitis [with the exception of&#xD;
             diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome or Wegener&#xD;
             syndrome [granulomatosis with polyangiitis], Graves' disease, rheumatoid arthritis,&#xD;
             hypophysitis, uveitis, etc.). The following are exceptions to this criterion:&#xD;
&#xD;
               1. Patients with vitiligo or alopecia&#xD;
&#xD;
               2. Patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on&#xD;
                  hormone replacement&#xD;
&#xD;
               3. Patients with any chronic skin condition that not required systemic therapy&#xD;
&#xD;
               4. Patients without active disease in the last 5 years may be included but only&#xD;
                  after consultation with the study physician&#xD;
&#xD;
               5. Patients with celiac disease controlled by diet alone&#xD;
&#xD;
          -  Uncontrolled intercurrent illness (i.e. active infection, symptomatic congestive heart&#xD;
             failure, uncontrolled hypertension, unstable angina pectoris, interstitial lung&#xD;
             disease, serious chronic gastrointestinal conditions (i.e. diarrhea), psychiatric&#xD;
             illness)&#xD;
&#xD;
          -  History of another primary malignancy in the last 5 years, except adequately treated&#xD;
             nonmelanoma skin cancer, adequately treated carcinoma in situ (without evidence of&#xD;
             disease)&#xD;
&#xD;
          -  History of leptomeningeal carcinomatosis, or brain metastases&#xD;
&#xD;
          -  Known HIV positive and/or active infection including tuberculosis (clinical evaluation&#xD;
             that includes clinical history, physical examination and radiographic findings, and TB&#xD;
             testing in line with local practice), hepatitis B (known positive HBV surface antigen&#xD;
             (HBsAg) result), hepatitis C. Patients with a past or resolved HBV infection (defined&#xD;
             as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are&#xD;
             eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if&#xD;
             polymerase chain reaction is negative for HCV RNA.&#xD;
&#xD;
          -  Current or prior use of immunosuppressive medication within 14 days before the first&#xD;
             dose.The following are exceptions to this criterion:&#xD;
&#xD;
               1. Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra&#xD;
                  articular injection)&#xD;
&#xD;
               2. Systemic corticosteroids at physiologic doses not exceeding 10 mg/day of&#xD;
                  prednisone or its equivalent&#xD;
&#xD;
               3. Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication)&#xD;
&#xD;
          -  Receipt of live attenuated vaccine within 30 days prior to the first dose of IMP&#xD;
&#xD;
          -  Participation in another clinical trial with an investigational product within the&#xD;
             last 30 days (unless during follow-up period of an interventional study)&#xD;
&#xD;
          -  Known hypersensitivity to one of the ingredients&#xD;
&#xD;
          -  Medical or psychological conditions that would jeopardize an adequate and orderly&#xD;
             completion of the trial&#xD;
&#xD;
          -  Pregnancy, lactation and contraception&#xD;
&#xD;
               1. Women who are pregnant, nursing or who plan to become pregnant while in the trial&#xD;
&#xD;
               2. Women of child-bearing potential (WOCBP) and men who are able to father a child,&#xD;
                  unwilling to be abstinent or use highly effective methods of birth control that&#xD;
                  result in a low failure rate of less than 1% per year when used consistently and&#xD;
                  correctly beginning at informed consent, for the duration of drug treatment and&#xD;
                  for the drug out washout period (90 days after last dose of Durvalumab and/or 6&#xD;
                  months after last dose of cisplatin and etoposide).&#xD;
&#xD;
          -  Patients who are legally institutionalized&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Wehler, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Gießen Marburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas Wehler, Professor Dr med</last_name>
    <phone>+49 641985</phone>
    <phone_ext>58544</phone_ext>
    <email>Thomas.wehler@innere.med.uni-giessen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Ehrlich, MD</last_name>
    <phone>+49 6131 17</phone>
    <phone_ext>9945</phone_ext>
    <email>topsch@izks-mainz.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Klinik Löwenstein gGmbH</name>
      <address>
        <city>Löwenstein</city>
        <state>Baden-Würtemberg</state>
        <zip>74245</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klinikverbund Allgäu gGmbH</name>
      <address>
        <city>Immenstadt</city>
        <state>Bayern</state>
        <zip>87509</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schuhmann, Prof Dr med</last_name>
      <email>christian.schuhmann@klinikverbund-allgaeu.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Gießen Marburg</name>
      <address>
        <city>Gießen</city>
        <state>Hessen</state>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wehler, Prof Dr med</last_name>
      <email>Thomas.wehler@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Kassel GmbH-Klinik für Onkologie und Hämatologie</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Wolf, Prof Dr med</last_name>
      <email>martin.wolf.studie@gnh.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KEM GmbH</name>
      <address>
        <city>Essen</city>
        <state>NRW</state>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Christoph, PD DR med</last_name>
      <email>studiensekretariat@kem-med.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <state>NRW</state>
        <zip>D 58675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Reinacher-Schick, Professor</last_name>
      <email>anke.reinbacher@rub.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Kirschner, Dr. med.</last_name>
      <email>mkirschner@ukaachen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asklepios Fachkliniken Muenchen Gauting</name>
      <address>
        <city>München Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Niels Reinmuth, Dr. med.</last_name>
      <email>n.reinmuth@asklepios.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Johannes Gutenberg University Mainz</investigator_affiliation>
    <investigator_full_name>Michael Hopp</investigator_full_name>
    <investigator_title>Head of Interdisciplinary Center for Clinical Studies (IZKS)</investigator_title>
  </responsible_party>
  <keyword>LD-SCLC</keyword>
  <keyword>lung cancer</keyword>
  <keyword>durvalumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

